Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

Breast Neoplasms 36Neoplasms 7Neoplasm Metastasis 7Endometrial Neoplasms 7Ovarian Neoplasms 5Triple Negative Breast Neoplasms 4Breast Diseases 3Brain Neoplasms 3Sarcoma 2Neoplasms by Site 2Meningioma 2Glioblastoma 2Fallopian Tube Neoplasms 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Sarcoma, Kaposi 1Retinoblastoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neurofibromatosis 1 1Neoplasm, Residual 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1

Interventions

regorafenib 1enasidenib 1capivasertib 1abemaciclib 1Weight-Bearing 1Taxes 1Standard of Care 1Range of Motion, Articular 1Paclitaxel 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Chondrosarcoma × abemaciclib × Clear all
NCT04040205 2025-07-20

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Medical College of Wisconsin

Phase 2 Recruiting
44 enrolled
Other solid neoplasmSarcoma

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡